Status and phase
Conditions
Treatments
About
Objective of the trial is to study if famotidine add-on treatment is more effective than placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient response to ongoing antipsychotic treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Jesper Ekelund, MD,PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal